Products in Pipeline
* PNV is a vaccine addressing the following bacteria:
- Escherichia coli
- Klebsiella pneumoniae
- Staphylococcus aureus (incl. MRSA and VRSA)
- Streptococcus pneumoniae
- Streptococcus agalactiae (GBS)
**UNImAb are monoclonal antibodies addressing the following bacteria:
- Escherichia coli
- Klebsiella pneumoniae
- Staphylococcus aureus (incl. MRSA and VRSA)
- Streptococcus pneumoniae
- Streptococcus agalactiae (GBS)
PNV
Immunethep has developed the Paragon Novel Vaccine (PNV), a breakthrough vaccine providing effective protection against bacterial infections caused by 5 different bacteria: Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli, and Streptococcus agalactiae (GBS).
PNV works by neutralizing an extracellular form of bacterial GAPDH, without blocking the human GAPDH. This will enable the host immune system to fight the infection and eliminate the bacteria.
Preclinical trials performed on animal models have demonstrated high levels of efficacy against all 5 bacteria with a strong safety profile.
PNV is a peptide-based immunotherapy that is stable at high temperatures and it is not freezing sensitive.
Once on the market, PNV will become the world’s first vaccine preventing multiple bacterial infections for all its invasive serotypes, including multi-resistant strains.
UNImAb
Immunethep is developing a therapeutic immunotherapy based on monoclonal antibodies with the following characteristics:
- Monoclonal antibody (IgG1) targeting bacterial GAPDH;
- Treats infection from all invasive serotypes of multiple bacteria;
- Very low probability of inducing resistance;
- Microbiome friendly